Text Size

Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy

This study is currently recruiting participants.
Verified July 2012 by Yonsei University
Sponsor:
Information provided by (Responsible Party):
Yonsei University
ClinicalTrials.gov Identifier:
NCT01648517
First received: July 1, 2012
Last updated: July 25, 2012
Last verified: July 2012
History of Changes
  Purpose

This is a prospective phase II trial, in patients with unresectable or metastatic NSCLC using chemotherapy regimens which will be defined according to the mRNA expression of ERCC1 and RRM1 of the tumor cells.


Condition Intervention Phase
Non-small Cell Lung Carcinoma
 Drug: chemotherapy
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources

Further study details as provided by Yonsei University:

Primary Outcome Measures:
  • overall Response Rate [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months ] [ Designated as safety issue: No ]

    ORR was assessed by tumor response evaluation according to RECIST 1.1 at every 8 weeks. Tumor assessments will continue about every 8 weeks until disease progression or initiation of subsequent anticancer treatment.

    (If PR or CR was first documented, confirmation assessment was done between 4 weeks and 8 weeks)



Secondary Outcome Measures:
  • Progression free survival [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
  • overall survival [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
  • duration of response [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
  • disease control rate [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 162
Study Start Date: July 2012
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A
Genomic-driven dual agent chemotherapy Chemotherapy will consist of the assigned two drugs according to ERCC1 and RRM1 mRNA expression level A1: docetaxel + vinorelbine (DV) A2: gemcitabine + vinorelbine (GV) A3: docetaxel + carboplatin (DC) A4: gemcitabine + carboplatin (GC)
 Drug: chemotherapy
A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
Other Names:
  • Docetaxel - Taxotere
  • Vinorelbine: Sandoz vinorelbine
  • Carboplatin: Carplan
  • Gemcitabine: Gemzar
Active Comparator: Arm B
standard of care All control arm patients received standard platinum-based doublet chemotherapy with docetaxel plus carboplatin
 Drug: chemotherapy
Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
Other Names:
  • Docetaxel - Taxotere
  • Carboplatin: Carplan

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed unresectable advanced or metastatic non-small cell lung cancer (NSCLC) (stage IIIB or IV)
  2. Chemotherapy naïve patient (Previous adjuvant or neoadjuvant chemotherapy allowed if the last dose was administered equal to or greater than 6 months ago.)
  3. Age > 18
  4. Performance status 0 to 2 by Eastern Cooperative Oncology Group (ECOG) criteria
  5. At least one measurable lesion by Response Evaluation Criteria In Solid Tumors (RECIST)
  6. Adequate organ functions (assessed within 14 days of starting treatment) 1) Bone marrow: Absolute neutrophil count ≥ 1,500/mm³, Platelet count ≥ 100,000/mm³, Hemoglobin ≥ 9.0 mg/dL 2) Liver: Total bilirubin ≤ 1.5 x ULN; aspartic transaminase (AST) and alanine transaminase (ALT), alkaline phosphatase(ALP) ≤ 2.5 x ULN 3) Kidney: Serum creatinine ≤ 1.5 x ULN
  7. Signed informed consent document

Exclusion Criteria:

  1. Clinically significant serious illness or medical condition (infection)
  2. Prior systemic chemotherapy or immunotherapy for advanced NSCLC.
  3. Presence of uncontrolled brain or leptomeningeal metastases
  4. Prior radiotherapy within 3 weeks of starting treatment
  5. Peripheral neuropathy equal to or greater than grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
  6. Pregnant or lactating
  7. Absolute contraindication of corticosteroid use
  8. Patients with a history of severe hypersensitivity reaction to docetaxel, carboplatin, vinorelbine or gemcitabine
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01648517

Contacts
Contact: Byoung Chul Cho, MD, PhD 82-2-2228-8126 cbc1871@yuhs.ac

Locations
Korea, Republic of
Severance Hospital Recruiting
Seoul, Korea, Republic of, 120-752
Contact: Byoung Chul Cho, MD, PhD     82-2-2228-8126     cbc1871@yuhs.ac    
Sponsors and Collaborators
Yonsei University
  More Information

No publications provided

Responsible Party: Yonsei University
ClinicalTrials.gov Identifier: NCT01648517     History of Changes
Other Study ID Numbers: 4-2008-0132
Study First Received: July 1, 2012
Last Updated: July 25, 2012
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)

Keywords provided by Yonsei University:
on-small cell lung carcinoma
chemotherapy naive patient

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Gemcitabine
Vinorelbine
 Docetaxel
Carboplatin
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Radiation-Sensitizing Agents

ClinicalTrials.gov processed this record on June 18, 2013